D9815

Doxazosin mesylate

Name: Doxazosin mesylate
Brand: SIGMA

≥97% (HPLC), powder

Synonym(s):

1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-[4-(1,4-benzodioxan-2-yl)carpiperazin-1-yl)]-6,7-dimethoxyquinazoline mesylate, Doxazosin methanesulfonate

Select a Size

All Photos(3)

About This Item

Empirical Formula (Hill Notation):

C₂₃H₂₅N₅O₅ · CH₃SO₃H

CAS Number:

77883-43-3

Molecular Weight:

547.58

NACRES:

NA.77

PubChem Substance ID:

24278398

UNSPSC Code:

12352200

MDL number:

MFCD00216023

Product Name

Doxazosin mesylate, ≥97% (HPLC), powder

InChI key

VJECBOKJABCYMF-UHFFFAOYSA-N

SMILES string

CS(O)(=O)=O.COc1cc2nc(nc(N)c2cc1OC)N3CCN(CC3)C(=O)C4COc5ccccc5O4

InChI

1S/C23H25N5O5.CH4O3S/c1-30-18-11-14-15(12-19(18)31-2)25-23(26-21(14)24)28-9-7-27(8-10-28)22(29)20-13-32-16-5-3-4-6-17(16)33-20;1-5(2,3)4/h3-6,11-12,20H,7-10,13H2,1-2H3,(H2,24,25,26);1H3,(H,2,3,4)

assay

≥97% (HPLC)

form

powder

color

white

Quality Level

200

Gene Information

human ... ADRA1A(148), ADRA1B(147), ADRA1D(146)
rat ... Adra1a(29412), Adra1b(24173), Adra1d(29413)

Looking for similar products? Visit Product Comparison Guide

Biochem/physiol Actions

α₁-adrenoceptor antagonist; relaxes smooth muscles of the prostate

Features and Benefits

This compound is a featured product for Neuroscience research. Click here to discover more featured Neuroscience products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

Storage Class

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Effects of MDMA alone and after pretreatment with reboxetine, duloxetine, clonidine, carvedilol, and doxazosin on pupillary light reflex.

Cédric M Hysek et al.

Psychopharmacology, 224(3), 363-376 (2012-06-16)

Pupillometry can be used to characterize autonomic drug effects. This study was conducted to determine the autonomic effects of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy), administered alone and after pretreatment with reboxetine, duloxetine, clonidine, carvedilol, and doxazosin, on pupillary function. Infrared pupillometry was

Efficacy of medical expulsive treatment with doxazosin in pediatric patients.

Sakip Erturhan et al.

Urology, 81(3), 640-643 (2013-01-25)

To evaluate the possible efficacy of an α1 blocker (doxazosin) therapy on the management and disease course in pediatric patients with distal ureteral stones. A total of 45 patients (24 boys and 21 girls) with a single lower ureteral stone

A small molecule agonist of EphA2 receptor tyrosine kinase inhibits tumor cell migration in vitro and prostate cancer metastasis in vivo.

Aaron Petty et al.

PloS one, 7(8), e42120-e42120 (2012-08-24)

During tumor progression, EphA2 receptor can gain ligand-independent pro-oncogenic functions due to Akt activation and reduced ephrin-A ligand engagement. The effects can be reversed by ligand stimulation, which triggers the intrinsic tumor suppressive signaling pathways of EphA2 including inhibition of

Gene panels to help identify subgroups at high and low risk of coronary heart disease among those randomized to antihypertensive treatment: the GenHAT study.

Amy I Lynch et al.

Pharmacogenetics and genomics, 22(5), 355-366 (2012-03-06)

To identify panels of genetic variants that predict treatment-related coronary heart disease (CHD) outcomes in hypertensive patients on one of four different classes of initial antihypertensive treatment. The goal was to identify subgroups of individuals on the basis of their

Noradrenergic α₁ receptor antagonist treatment attenuates positive subjective effects of cocaine in humans: a randomized trial.

Thomas F Newton et al.

PloS one, 7(2), e30854-e30854 (2012-02-10)

Preclinical research implicates dopaminergic and noradrenergic mechanisms in mediating the reinforcing effects of drugs of abuse, including cocaine. The objective of this study was to evaluate the impact of treatment with the noradrenergic α(1) receptor antagonist doxazosin on the positive

View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service